Please ensure Javascript is enabled for purposes of website accessibility

Is Johnson & Johnson a Buy for Summer 2021?

By Zhiyuan Sun – Updated May 25, 2021 at 10:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This pharmaceutical giant and troubled coronavirus vaccine maker has lagged behind the overall market. Is it a decent contrarian play?

Despite the economic turmoil of the past year, the S&P 500 has delivered a magnificent 43% year-over-year rally. But those gains were far from uniform across all stocks, and indeed, many were left behind. One of these relative laggards was blue-chip pharmaceutical Johnson & Johnson (JNJ 0.33%): Its stock has underperformed the index by more than 20 percentage points over the past 12 months. 

That was a major disappointment for shareholders, many of whom were betting that a successful J&J coronavirus vaccine would lift the company's shares. But is this pharma stock a buy today? 

Woman receiving coronavirus vaccine.

Image source: Getty Images.

What happened? 

Last year, Johnson & Johnson (with $1 billion in federal support) developed a one-dose coronavirus vaccine that was found to be 72% effective in clinical trials. It offered a couple of significant upsides compared to the mRNA vaccines that the FDA also approved for use: It has much less demanding cold-storage requirements, so it can be distributed in places that lack expensive cold-chain infrastructure. And its single-shot regimen gives it an advantage in terms of inoculating populations that are harder to reach.

However, the rollout of that vaccine, dubbed Ad26.CoV2.S, has been less than rosy. In fact, Johnson & Johnson's vaccine now represents as little as 5% of overall vaccine volume in states like California.

Public image problems have plagued Ad26.CoV2.S since its release. First, people noticed that its distribution footprint correlated with communities in the poorest zip codes and rural areas. This related to the fact that it could be sent easily to places that the other vaccines could not be, but the disparity nonetheless led to baseless conspiracy theories alleging that the distribution strategy was racist in nature, as Ad26.CoV2.S had a somewhat lower efficacy rate than the Pfizer and Moderna vaccines

Then, the U.S. Food and Drug Administration uncovered that the company's contract manufacturer, Emergent Biosciences (EBS -1.32%), was unqualified to produce vaccines at its Baltimore plant. Among many other issues, Emergent Biosciences employees tainted as many as 15 million doses of Johnson & Johnson's vaccine with ingredients meant for AstraZeneca's coronavirus vaccine. 

AstraZeneca then had to relocate the production of its vaccine abroad to the Netherlands. On top of that, 28 people developed serious blood clots after receiving Ad26.CoV2.S. That's an extremely rare result considering that 8.7 million people had been given the vaccine. Even so, it contributed to a widespread perception that Johnson & Johnson's vaccine is inferior, so people are largely choosing the mRNA shots instead when they can, even if it means a longer wait to get their jabs.

Looking past the vaccine drama 

Investing in Johnson & Johnson stock should never have been about speculating on its COVID-19 vaccine potential in the first place. Last year, it committed to selling Ad26.CoV2.S on a not-for-profit basis for the duration of the pandemic.

Meanwhile, during the first quarter, the pharma giant's revenue increased by 7.9% year over year to $22.3 billion. At the same time, its earnings per share improved 6.9% to $2.32. That growth is particularly impressive as Johnson & Johnson is already a mega-corporation.

There was notable growth in sales worldwide across its pharmaceuticals and medical devices segments, though it was held back a bit by a small decline in its consumer health segment, where sales fell for certain supplies that had been in high demand early in the pandemic

A key driver behind Johnson & Johnson's long-term growth is its commitment to research and development. Over $2.3 billion of the company's sales are reinvested back into innovating new drugs. It has 10 drug approval requests pending in indications ranging from multiple myeloma to pulmonary arterial hypertension to schizophrenia. Johnson & Johnson has a further five candidates awaiting submission to regulators, and four treatments in phase 3 clinical trials that have data readouts due by the end of the year.

What's the verdict? 

Right now, the average pharma stock trades at about 5 times sales and 123 times earnings, and most companies in the space don't pay a dividend. Meanwhile, Johnson & Johnson stock has a valuation of 4.8 times revenue, but only 18 times earnings. Its dividend yield is also decent at 2.37%, noticeably better than the 1.4% average yield of the S&P 500.

Overall, given the strength of its core operations, its great R&D pipeline, and its cheap valuation, Johnson & Johnson is a solid stock to buy now. Investors should consider that its shares have significant untapped value, regardless of whether it ultimately sees financial success from its coronavirus vaccine program. 

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$166.72 (0.33%) $0.54
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.58 (-3.07%) $-1.73
Pfizer Inc. Stock Quote
Pfizer Inc.
$44.08 (-1.10%) $0.49
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$20.86 (-1.32%) $0.28
Moderna, Inc. Stock Quote
Moderna, Inc.
$123.64 (-0.55%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.